Search results
Results from the WOW.Com Content Network
Location of Belgium. Belgium is a sovereign state in Western Europe bordered by France, the Netherlands, Germany, Luxembourg, and the North Sea. It is a small, densely populated country which covers an area of 30,528 square kilometres (11,787 sq mi) and has a population of about 11 million people.
Pages in category "Pharmaceutical companies of Belgium" The following 11 pages are in this category, out of 11 total. This list may not reflect recent changes .
Recherche et Industrie Thérapeutiques (R.I.T.) was founded in Genval, Belgium, as a penicillin factory in 1945 by Dr Pieter De Somer, who later became the founder of the Rega Institute for Medical Research and rector of the Katholieke Universiteit Leuven (Leuven, Belgium). The industrialist Jean Lannoye provided the funding for the company.
Janssen Pharmaceuticals was the first Western pharmaceutical company to set up a pharmaceutical factory in the People's Republic of China. [27] In 1976, Paul Janssen met Ma Haide (born George Shafik Hatem), a Lebanese-American doctor who had started working in China in 1933. After three days of meetings, the two agreed to bring a modernized ...
This list is based on the Forbes Global 2000, which ranks the world's 2,000 largest publicly traded companies.The Forbes list takes into account a multitude of factors, including the revenue, net profit, total assets and market value of each company; each factor is given a weighted rank in terms of importance when considering the overall ranking.
Fagron supplies products and services to professionals and institutions in the healthcare sector in Europe, the United States, Brazil and Argentina. The company comprises four company divisions: Fagron Group supplies products for pharmaceutical drug compounding to hospitals and pharmacists. This division also sells products under the Fagron ...
UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium.UCB is an international company with revenue of €4.178 billion in 2016 [2] which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. [2]
In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company. [3] [4] However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business. [5] In January 2018, they were acquired by Sanofi for $4.8 ...